Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 136

The DOI matches its Crossref record.

Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential

Prade, Lars, Engh, Richard A, Girod, Andreas, Kinzel, Volker, Huber, Robert, Bossemeyer, Dirk · 1997 · Structure

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0969-2126(97)00310-9

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 51

  1. Omura, 1977, New alkaloid AM-2282 of Streptomyces origin – taxonomy, fermentation, isolation and preliminary characterization, J. Antibiot, 30, 275, 10.7164/antibiotics.30.275 · DOI · Paper page
  2. Tamaoki, 1991, Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors, Methods Enzymol, 201, 340, 10.1016/0076-6879(91)01030-6 · DOI · Paper page
  3. Gadbois, 1992, Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases, Biochem. Biophys. Res. Commun, 184, 80, 10.1016/0006-291X(92)91160-R · DOI
  4. Tamaoki, 1986, Staurosporine, a potent inhibitor of phospholipid/Ca2+ dependent protein kinase, Biochem. Biophys. Res. Commun, 135, 397, 10.1016/0006-291X(86)90008-2 · DOI · Paper page
  5. Herbert, 1990, Characterization of specific binding sites for [3H]-staurosporine on various protein kinases, Biochem. Biophys. Res. Commun, 171, 189, 10.1016/0006-291X(90)91375-3 · doi:10.1016/0006-291x(90)91375-3
  6. Nakano, 1987, Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60, J. Antibiot. Tokyo, 40, 706, 10.7164/antibiotics.40.706 · DOI · Paper page
  7. Secrist, 1990, Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine, J. Biol. Chem, 265, 20394, 10.1016/S0021-9258(17)30517-3 · doi:10.1016/s0021-9258(17)30517-3
  8. Fujita-Yamaguchi, 1988, Characterization of receptor tyrosine-specific protein kinases by the use of inhibitors. Staurosporine is a 100-times more potent inhibitor of insulin receptor than IGF-I receptor, Biochem. Biophys. Res. Commun, 157, 955, 10.1016/S0006-291X(88)80967-7 · doi:10.1016/s0006-291x(88)80967-7
  9. Raffioni, 1995, Staurosporine causes epidermal growth factor to induce differentiation in PC12 cells via receptor up-regulation, J. Biol. Chem, 270, 7568, 10.1074/jbc.270.13.7568 · DOI
  10. Stanwell, 1996, Staurosporine induces a complete program of terminal differentiation in neoplastic mouse keratinocytes via activation of protein kinase C, Carcinogenesis, 17, 1259, 10.1093/carcin/17.6.1259 · doi:10.1093/carcin/17.6.1259
  11. Wiesner, 1996, Staurosporine induces programmed cell death in embryonic neurons and activation of the ceramide pathway, J. Neurochem, 66, 1418, 10.1046/j.1471-4159.1996.66041418.x · DOI · Paper page
  12. Raff, 1993, Programmed cell death and the control of cell survival: lessons from the nervous system, Science, 262, 695, 10.1126/science.8235590 · DOI · Paper page
  13. Jacobson, 1994, Programmed cell death and Bcl-2 protection in the absence of a nucleus, EMBO J, 13, 1899, 10.1002/j.1460-2075.1994.tb06459.x · DOI · Paper page
  14. Akinaga, 1991, Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models, Cancer Res, 51, 4888
  15. Meyer, 1989, A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity, Int. J. Cancer, 43, 851, 10.1002/ijc.2910430519 · DOI · Paper page
  16. Yanagihara, 1991, Staurosporine: an effective inhibitor for Ca2+/calmodulin-dependent protein kinase II, J. Neurochem, 56, 294, 10.1111/j.1471-4159.1991.tb02595.x · DOI
  17. Meggio, 1995, Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2, Eur. J. Biochem, 234, 317, 10.1111/j.1432-1033.1995.317_c.x · DOI · Paper page
  18. Davis, 1992, Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity, J. Med. Chem, 35, 994, 10.1021/jm00084a004 · DOI · Paper page
  19. Engh, 1996, Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89 – structural implications for selectivity, J. Biol. Chem, 271, 26157, 10.1074/jbc.271.42.26157 · DOI · Paper page
  20. Schulze-Gahmen, 1996, High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design, J. Med. Chem, 39, 4540, 10.1021/jm960402a · DOI · Paper page
  21. De-Azevedo, 1996, Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase, Proc. Natl. Acad. Sci. USA, 93, 2735, 10.1073/pnas.93.7.2735 · DOI · Paper page
  22. Xu, 1996, Structural basis for selectivity of the isoquinoline sulfonamide family of protein kinase inhibitors, Proc. Natl. Acad. Sci. USA, 93, 6308, 10.1073/pnas.93.13.6308 · DOI
  23. Mohammadi, 1997, Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors, Science, 276, 955, 10.1126/science.276.5314.955 · DOI · Paper page
  24. Tong, 1997, A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket, Nat. Struct. Biol, 4, 311, 10.1038/nsb0497-311 · DOI · Paper page
  25. Furet, 1995, Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411, J. Comput. Aided Mol. Des, 9, 465, 10.1007/BF00124317 · DOI
  26. Takagi, 1996, Inhibition mechanisms of staurosporine and h7 to cAMP-dependent protein kinase through docking study, Chem. Pharmaceut. Bull, 44, 618, 10.1248/cpb.44.618 · doi:10.1248/cpb.44.618
  27. Wiemann, 1992, Cloning of the C alpha catalytic subunit of the bovine cAMP-dependent protein kinase, Biochim. Biophys. Acta, 1171, 93, 10.1016/0167-4781(92)90144-O · DOI
  28. Knighton, 1991, Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase, Science, 253, 407, 10.1126/science.1862342 · DOI · Paper page
  29. Narayana, 1997, Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of cAMP-dependent protein kinase complexed with the peptide inhibitor PKI(5–24) and adenosine, Biochemistry, 36, 4438, 10.1021/bi961947+ · DOI
  30. Zheng, 1993, Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor, Biochemistry, 32, 2154, 10.1021/bi00060a005 · DOI · Paper page
  31. Bossemeyer, 1993, Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 Å structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5–24), EMBO J, 12, 49, 10.1002/j.1460-2075.1993.tb05725.x · DOI · Paper page
  32. Karlsson, 1993, The crystal structure of the mammalian catalytic subunit of cAMP-dependent protein kinase and an inhibitor peptide displays an open conformation, Acta Cryst. D, 49, 381, 10.1107/S0907444993002306 · DOI
  33. Narayana, 1997, A binary complex of the catalytic subunit of cAMP-dependent protein kinase and adenosine further defines conformational flexibility, Structure, 5, 921, 10.1016/S0969-2126(97)00246-3 · DOI · Paper page
  34. Zheng, 1993, Crystal structures of the myristylated catalytic subunit of cAMP-dependent protein kinase reveal open and closed conformations, Protein Sci, 2, 1559, 10.1002/pro.5560021003 · DOI · Paper page
  35. Hanks, 1991, Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members, Methods Enzymol, 200, 38, 10.1016/0076-6879(91)00126-H · DOI · Paper page
  36. Knighton, 1993, 2.0 Å refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with a peptide inhibitor and detergent, Acta Cryst. D, 49, 357, 10.1107/S0907444993000502 · DOI
  37. Lew, 1997, Synergistic binding of nucleotides and inhibitors to cAMP-dependent protein kinase examined by acrylodan fluorescence spectroscopy, J. Biol. Chem, 272, 1507, 10.1074/jbc.272.3.1507 · doi:10.1074/jbc.272.3.1507
  38. Hartl, 1983, Adenosine cyclic 3′,5′-monophosphate dependent protein kinase: interaction of the catalytic subunit and holoenzyme with linbenzoadenine nucleotides, Biochemistry, 22, 2347, 10.1021/bi00279a007 · doi:10.1021/bi00279a007
  39. Schulze-Gahmen, 1995, Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine, Proteins, 22, 378, 10.1002/prot.340220408 · DOI · Paper page
  40. Bossemeyer, 1994, The glycine-rich sequence of protein kinases: a multifunctional element, Trends Biochem. Sci, 19, 201, 10.1016/0968-0004(94)90022-1 · DOI · Paper page
  41. Longenecker, 1996, Three-dimensional structure of mammalian casein kinase I: molecular basis for phosphate recognition, J. Mol. Biol, 257, 618, 10.1006/jmbi.1996.0189 · DOI
  42. Herberg, 1993, Expression of the catalytic subunit of cAMP-dependent protein kinase in Escherichia coli – multiple isozymes reflect different phosphorylation states, Protein Eng, 6, 771, 10.1093/protein/6.7.771 · doi:10.1093/protein/6.7.771
  43. Girod, 1996, In vivo activation of recombinant cAPK catalytic subunit active site mutants by coexpression of the wild type enzyme, evidence for intermolecular cotranslational phosphorylation, FEBS Lett, 391, 121, 10.1016/0014-5793(96)00717-X · DOI
  44. 1994, The CCP4 suite: programs for protein crystallography, Acta Cryst. D, 50, 760, 10.1107/S0907444994003112 · DOI · Paper page
  45. Navaza, 1994, AMoRe: an automated package for molecular replacement, Acta Cryst. A, 50, 157, 10.1107/S0108767393007597 · DOI · Paper page
  46. Brünger, 1992, Free R-value – a novel statistical quantity for assessing the accuracy of crystal structures, Nature, 355, 472, 10.1038/355472a0 · DOI · Paper page
  47. Engh, 1991, Accurate bond and angle parameters for X-ray protein structure refinement, Acta Cryst. A, 47, 392, 10.1107/S0108767391001071 · DOI · Paper page
  48. Jones, 1991, Improved methods for building protein models in electron-density maps and location of errors in these models, Acta Cryst. A, 47, 110, 10.1107/S0108767390010224 · DOI · Paper page
  49. Furusaki, 1978, X-ray crystal-structure of staurosporine – new alkaloid from a Steptomyces strain, J. Chem. Soc. Chem. Commun, 18, 800, 10.1039/C39780000800 · doi:10.1039/c39780000800
  50. Funato, 1994, Absolute configuration of staurosporine by X-ray analysis, Tetrahedron Lett, 35, 1251, 10.1016/0040-4039(94)88036-0 · doi:10.1016/0040-4039(94)88036-0
  51. Kleywegt, 1994, A super position, ESF/CCP4 Newsletter, 31, 9

Cited by

See all 136

Metadata

Authors
Prade, L., Engh, R. A., Girod, A., Kinzel, V., Huber, R., & Bossemeyer, D.
Venue
Structure
Publisher
Elsevier BV
Published
1997-12
Volume
5
Issue
12
Pages
1627-1637
ISSN
0969-2126
Cited by
136
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. https://app.cochat.ai/papers/10.1016/s0969-2126(97)00310-9
The paper
Prade, L., Engh, R. A., Girod, A., Kinzel, V., Huber, R., & Bossemeyer, D. (1997). Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure. https://doi.org/10.1016/s0969-2126(97)00310-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.